We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Regeneron’s CD20xCD3 bispecific antibody has achieved an 80% complete response rate in a small trial of patients with relapsed or refractory follicular lymphoma....